CLDX (Celldex Therapeutics) 3-1 Month Momentum %: -4.55% (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $34.82
GF Value $7.58
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics 3-1 Month Momentum %?

Celldex Therapeutics CLDX -1.64% 57 3-1 Month Momentum % is -4.55% as of Jul. 17, 2026. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $7.58 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,389 Biotechnology companies, Celldex Therapeutics ranks better than 65.44% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-17), Celldex Therapeutics's 3-1 Month Momentum % is -4.55%.

The industry rank for Celldex Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

CLDX's 3-1 Month Momentum % is ranked better than
65.44% of 1389 companies
in the Biotechnology industry
Industry Median: -13.25 vs CLDX: -4.55

Celldex Therapeutics  (NAS:CLDX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Celldex Therapeutics 3-1 Month Momentum % Related Terms

CLDX vs TARS, KLRA, IRON: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Celldex Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celldex Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's 3-1 Month Momentum % falls into.


CLDX
57GF Score
Celldex Therapeutics Inc CLDX
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics  (NAS:CLDX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -4.55% mean?
Celldex Therapeutics (CLDX) has a 3-1 Month Momentum % of -4.55% as of Jul. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Celldex Therapeutics and its competitors. According to the industry distribution chart, Celldex Therapeutics ranks #480 out of 1389 companies in the Biotechnology industry, placing it in the top 34.6%.
Is Celldex Therapeutics' 3-1 Month Momentum % too high?
Celldex Therapeutics' current 3-1 Month Momentum % is -4.55%. Based on the distribution chart, Celldex Therapeutics ranks #480 out of 1389 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' 3-1 Month Momentum % compare to TARS and KLRA?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #480 out of 1389 companies for 3-1 Month Momentum %. This puts Celldex Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current 3-1 Month Momentum % is -4.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $34.82 — trading 359.4% above its estimated fair value. The current 3-1 Month Momentum % is -4.55%. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current 3-1 Month Momentum % is -4.55% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $34.82 is trading 359.4% above its estimated GF Value™ of $7.58. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • 3-1 Month Momentum %: -4.55%
  • GF Value™: $7.58 vs. price of $34.82 (359.4% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.82
Price
$7.58
GF Value